Colorectal cancer
Not yet recruitingStudy of ipilimumab, nivolumab, temozolomide and capecitabine in patients with chemotherapy-resistant metastatic colorectal cancer with specific genetic markers
Study of ipilimumab, nivolumab, temozolomide and capecitabine in patients with chemotherapy-resistant metastatic colorectal cancer with specific genetic markers
- Disease:Colorectal cancer
- Substances:CapecitabineIpilimumab+2
Denmark- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Odense University Hospital








